Shang­hai biotech up­start rais­es $50M, bags an­ti­body dis­cov­ery group and ramps up Boston unit

A new Shang­hai-based biotech up­start is tak­ing part of its $50 mil­lion A round to ac­quire an an­ti­body dis­cov­ery out­fit in Rot­ter­dam while blue­print­ing plans to jump­start a re­search site in the Boston area.

The Chi­nese com­pa­ny is Har­bour Bio­Med, run by Sanofi R&D vet Jing­song Wang and Liang Schweiz­er. They are buy­ing Har­bour An­ti­bod­ies, a spin­out of Eras­mus Uni­ver­si­ty which has been do­ing a se­ries of deals us­ing its trans­genic mouse mod­els to dis­cov­er new an­ti­bod­ies. And they are be­ing fi­nanced by Ad­van­tech Cap­i­tal and Leg­end Cap­i­tal, two in­creas­ing­ly promi­nent Chi­na-based life sci­ences in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.